{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:09:56Z","timestamp":1778929796807,"version":"3.51.4"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Sodium glucose co\u2010transporter 2 inhibitors (SGLT2i) and glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) are nephroprotective and their use is recommended for adults with chronic kidney disease (CKD). The role of SGLT2i and GLP\u20101 RAs in patients with acute kidney injury (AKI) is unknown. This systematic review aimed to estimate the effect of SGLT2i or GLP\u20101 RAs on clinical outcomes in AKI. We systematically searched Embase, MEDLINE, Scopus, Web of Science Core Collection, and clinical trials registries for observational studies and clinical trials from database inception to July 3, 2025. Included studies evaluated adults (\u2265\u200918\u2009years) with AKI during a hospitalization and compared patients subsequently exposed to either SGLT2i or GLP\u20101 RAs to a non\u2010exposed control group. Random effects meta\u2010analyses were performed. Six studies related to SGLT2i (five observational, one randomized trial) and one related to GLP\u20101 RAs (one observational) met eligibility criteria (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009432,048 patients). SGLT2i\/GLP\u20101 RA exposure was associated with lower odds of major adverse kidney events (MAKE) (OR 0.63, 95% CI 0.46\u20130.86) and all\u2010cause mortality [odds ratio (OR) 0.36, 95% confidence interval (CI) 0.21\u20130.62] compared to controls. The odds for kidney replacement therapy were lower with SGLT2i therapy in the three studies where it was evaluated (OR 0.61, 95% CI 0.40\u20130.93). Sensitivity analyses restricted to SGLT2i data were consistent with the overall findings [MAKE OR 0.63 (95% CI 0.42\u20130.95); Mortality OR 0.34 (95% CI 0.18, 0.65)]. Exposure to SGLT2i or GLP\u20101 RAs after AKI, examined primarily in observational studies, was associated with improved clinical outcomes. These findings are promising and warrant evaluation in randomized clinical trials.\n                  <\/jats:p>","DOI":"10.1002\/phar.70137","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:01:51Z","timestamp":1775631711000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 Inhibitors and GLP\u20101 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta\u2010Analysis"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-1487","authenticated-orcid":false,"given":"Erin F.","family":"Barreto","sequence":"first","affiliation":[{"name":"Department of Pharmacy Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yessie A.","family":"Garcia\u2010Nieves","sequence":"additional","affiliation":[{"name":"University of Puerto Rico at Ponce  Ponce Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan C.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Pharmaceutical Services Sanford Medical Center  Fargo North Dakota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ty H.","family":"Eder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Minnesota Medical Center  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle J.","family":"Gerberi","sequence":"additional","affiliation":[{"name":"Mayo Medical Libraries Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kianoush B.","family":"Kashani","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine Mayo Clinic  Rochester Minnesota USA"},{"name":"Division of Nephrology and Hypertension, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea G.","family":"Kattah","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen D.","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine University of California San Francsico  San Franciso California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather P.","family":"May","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[{"name":"Division of Endocrinology Diabetes, &amp; Nutrition, Department of Medicine University of Maryland School of Medicine  Baltimore Maryland USA"},{"name":"Division of Gerontology, Department of Epidemiology and Public Health University of Maryland School of Medicine  Baltimore Maryland USA"},{"name":"University of Maryland Institute for Health Computing  North Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Rule","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine Mayo Clinic  Rochester Minnesota USA"},{"name":"Division of Epidemiology, Department of Quantitative Health Sciences Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-5186","authenticated-orcid":false,"given":"Patrick M.","family":"Wieruszewski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00710113"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611391"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.036"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016010105"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.06.032"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519375"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.07.015"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02394-2"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15561"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022030306"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173675"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024jw0zaqg8"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2020.08.018"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236024"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123602"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.12.029"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.08.005"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"issue":"1","key":"e_1_2_11_24_1","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"Kellum J. a.","year":"2012","journal-title":"Kidney International"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.028"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_11_27_1","unstructured":"G. A.Wells B.Shea D.O'Connell et\u00a0al. \u201cThe Newcastle\u2010Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta\u2010Analyses [Internet] \u201d (2000) https:\/\/www.ohri.ca\/\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00443-2"},{"key":"e_1_2_11_30_1","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions (current version) | Cochrane [Internet] https:\/\/www.cochrane.org\/authors\/handbooks\u2010and\u2010manuals\/handbook\/current."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.09.021"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50199-y"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50050"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1356991"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000250"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000375"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.026"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10510"},{"key":"e_1_2_11_39_1","unstructured":"M. \u00c1.Mart\u00ednez\u2010RojasandN. A.Bobadilla Sodium\u2010Glucose Cotransporter 2 Inhibitors: A Novel Approach \u2026: Current Opinion in Nephrology and Hypertension https:\/\/journals.lww.com\/co\u2010nephrolhypertens\/fulltext\/9900\/sodium_glucose_cotransporter_2_inhibitors__a_novel.230.aspx."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm189"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.36230"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.665250"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112339"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100734"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0003672021"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241240409"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2025.01.005"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.70137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:40:31Z","timestamp":1778928031000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/phar.70137"],"URL":"https:\/\/doi.org\/10.1002\/phar.70137","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"2025-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70137"}}